A Two-Part, Single Rising Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MK-8723 in Healthy Adults and Patients With Immune Thrombocytopenia Purpura
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs MK 8723 (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 31 Aug 2018 Biomarkers information updated
- 13 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 31 Mar 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov.